Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Cardiovascular Research · 2024
DOI: 10.1093/cvr/cvae136 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Umidakhon Makhmudova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Genetic Therapy, Oligonucleotides, Antisense. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 194 Literaturangaben.
Abstract (Originalsprache)
Nucleic acid-based therapies are being rapidly developed for prevention and management of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the delivery, safety, and effectiveness of these therapeutics in the past decade. These therapies can also modulate therapeutic targets that cannot be sufficiently addressed using traditional drugs or antibodies. Among the nucleic acid-targeted therapeutics under development for CVD prevention are RNA-targeted approaches, including antisense oligonucleotides (ASO), small interfering RNAs (siRNA), and novel genome editing techniques. Genetic studies have identified potential therapeutic targets that are suggested to play a causative role in development and progression of CVD. RNA- and DNA-targeted therapeutics can be particularly well delivered to the liver, where atherogenic lipoproteins and angiotensinogen (AGT) are produced. Current targets in lipid metabolism include proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein A (ApoA), apolipoprotein C3 (ApoC3), angiopoietin-like 3 (ANGPTL3). Several large-scale clinical development programs for nucleic acid-targeted therapies in cardiovascular prevention are under way, which may also be attractive from a therapy adherence point of view, given the long action of these therapeutics. In addition to genome editing, the concept of gene transfer is presently under assessment in preclinical and clinical investigations as a potential approach for addressing low-density lipoprotein receptor deficiency. Furthermore, ongoing research is exploring the use of RNA-targeted therapies to treat arterial hypertension by reducing hepatic angiotensinogen (AGT) production. This review summarizes the rapid translation of siRNA and ASO therapeutics as well as gene editing into clinical studies to treat dyslipidemia and arterial hypertension for CVD prevention. It also outlines potential innovative therapeutic options that are likely relevant to the future of cardiovascular medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
- Friede Springer Cardiovascular Prevention Center at Charité, Hindenburgdamm 30, 12203 Berlin, Germany.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik/Centrum, Charitéplatz 1, 10117 Berlin, Germany.
- Department of Endocrinology and Metabolic Diseases, Charite Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
- Department of Clinical and Molecular Medicine, Sapienza University of Rome, Via di Grottarossa 1035-1039, Rome 00189, Italy.
- Cardiology Department, IRCCS San Raffaele Roma, Via di Valcannuta 250, Rome 00166, Italy.
ORCID-Profile: Umidakhon Makhmudova, Massimo Volpe, Ulf Landmesser
Zitieren
APA
Makhmudova, U., Steinhagen-Thiessen, E., Volpe, M., & Landmesser, U. (2024). Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae136
Vancouver
Makhmudova U, Steinhagen-Thiessen E, Volpe M, Landmesser U. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae136
BibTeX
@article{Makhmudova2024,
author = {Makhmudova, Umidakhon and Steinhagen-Thiessen, Elisabeth and Volpe, Massimo and Landmesser, Ulf},
title = {Advances in nucleic acid-targeted therapies for cardiovascular disease prevention},
journal = {Cardiovascular Research},
year = {2024},
doi = {10.1093/cvr/cvae136}
}
EUVIMED